Okogen - Crunchbase Company Profile & Funding

Q: Where is Okogen's headquarters?

Okogen is located in Encinitas, California, United States.

Q: Who invested in Okogen?

Okogen has 2 investors including Medical Research Commercialisation Fund (MRCF) And Brandon Capital.

Q: When was the last funding round for Okogen?

Okogen closed its last funding round on obfuscated from a Undisclosed round.

Overview

Okogen

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Events

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Okogen

CB Rank

125494

Okogen is a developer of ophthalmic anti-infective drugs.

Founded

obfuscation

Private

Funding Round

Encinitas, California, United States

1-10

www.okogen.com

Biotechnology

Health Care

Pharmaceutical

Funding Rounds

Funding Round

OBF

obfuscation

Venture - Series Unknown

OBF

obfuscation

Series A

OBF

obfuscation

Details

Legal Name

Okogen, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Bradford Conlan, Brian Strem, Eric Daniels

About the Company

Okogen serves the needs of adults and children with ocular infections by developing therapies to reduce suffering, improve quality of life, and preserve vision.The company’s efforts are focused on infectious ocular diseases where treatments are either not available or unsatisfactory.

Predictions & Insights

Growth Insight

See this Growth Insight

Okogen is

Lorem

to be growing

Top Contributing Factors

Merger or Acquisition

Growth Prediction

See this Growth Prediction

Products & Services

OKG-0303

A triple-active combination eyedrop designed to treat both bacterial and viral acute infectious conjunctivitis by inhibiting viral replication, reducing redness and discharge, and providing antibacterial effects.

OKG-0301

A topical antiviral ophthalmic formulation that inhibits viral replication to treat acute adenoviral conjunctivitis.

Research & Development

Okogen is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Funding Round - Okogen	—	obfuscated obfuscation	—	Funding Round
obfuscated obfuscation	Funding Round - Okogen	—	obfuscated obfuscation	—	Funding Round
obfuscated obfuscation	Funding Round - Okogen	—	obfuscated obfuscation	—	Funding Round
obfuscated obfuscation	Funding Round - Okogen	—	obfuscated obfuscation	—	Funding Round
obfuscated obfuscation	Funding Round - Okogen	—	obfuscated obfuscation	—	Funding Round

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Funding Round - Okogen	—	obfuscated obfuscation	—	Funding Round
obfuscated obfuscation	Funding Round - Okogen	—	obfuscated obfuscation	—	Funding Round
obfuscated obfuscation	Funding Round - Okogen	—	obfuscated obfuscation	—	Funding Round
obfuscated obfuscation	Funding Round - Okogen	—	obfuscated obfuscation	—	Funding Round
obfuscated obfuscation	Funding Round - Okogen	—	obfuscated obfuscation	—	Funding Round

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Medical Research Commercialisation Fund (MRCF)	Yes	Series A - Okogen	Christopher Smith
Medical Research Commercialisation Fund (MRCF)	Yes	Series A - Okogen	Christopher Smith
Medical Research Commercialisation Fund (MRCF)	Yes	Series A - Okogen	Christopher Smith
Medical Research Commercialisation Fund (MRCF)	Yes	Series A - Okogen	Christopher Smith
Medical Research Commercialisation Fund (MRCF)	Yes	Series A - Okogen	Christopher Smith